IP Library Granted Patent US 7,455,797
Granted Patent B2
US 7,455,797 · App. 10/789,422 · Granted Nov 25, 2008

Method and apparatus for producing particles using supercritical fluid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,455,797
App. No.
10/789,422
Granted
Nov 25, 2008
Kind
B2
Abstract

The present invention provides a method of producing particles via a supercritical fluid processing technique, an apparatus for carrying out the method and the particles produced thereby. The method includes: (1) providing: a supercritical fluid; a first solvent that is soluble in the supercritical fluid; a second solvent that is substantially insoluble in the supercritical fluid and is at least partially soluble in or miscible with the first solvent; and a solute that is soluble in the first solvent and is substantially insoluble in the second solvent and the supercritical fluid; (2) contacting the first solvent, the second solvent and the solute together to form a solution; and (3) contacting the solution with the supercritical fluid to extract the first solvent from the solution and precipitate the solute in the form of particles that are suspended in the second solvent.

Claims (70)

1. A method of producing a particulate suspension comprising:

providing:

a supercritical fluid;

a first solvent that is soluble in the supercritical fluid;

a second solvent that is substantially insoluble in the supercritical fluid and is at least partially soluble in or miscible with the first solvent; and

a solute that is soluble in the first solvent and is substantially insoluble in the second solvent and the supercritical fluid;

contacting the first solvent, the second solvent and the solute together to form a solution;

contacting the solution with the supercritical fluid in an extraction chamber maintained at a temperature and pressure above the critical point of the supercritical fluid, the supercritical fluid extracting the first solvent from the solution and thereby causing the solute to precipitate in the form of particles that become suspended in the second solvent and thus form the particulate suspension; and

separating the particulate suspension from the first solvent by

flowing the first solvent out of the extraction chamber with the supercritical fluid via a backpressure regulator,

separately flowing the particulate suspension out of the extraction chamber and into a collection vessel,

isolating the collection vessel from the extraction chamber, and

draining the particulate suspension from the collection vessel.

2. The method according to claim 1 wherein the solute comprises a biologically active substance.

3. The method according to claim 1 wherein the supercritical fluid is selected from the group consisting of supercritical carbon dioxide, dimethylether, straight chain or branched chain C1-C6 alkanes and combinations thereof.

4. The method according to claim 1 wherein the solution further comprises a plurality of solutes and wherein the particles suspended in the second solvent comprise the plurality of solutes.

5. The method according to claim 4 wherein the plurality of solutes comprises a first solute comprising a biologically active substance and a second solute comprising an excipient selected from the group consisting of a polymer, a wax, a lipid and combinations thereof.

6. The method according to claim 1 wherein the first solvent comprises an organic solvent.

7. The method according to claim 6 wherein the first solvent is selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, alcohols, acetone, ethyl acetate and chloroform.

8. The method according to claim 1 wherein the second solvent is water.

9. The method according to claim 1 wherein the average particle size of the particles suspended in the second solvent is from about 10 nm to about 10 μm.

10. A method of producing an aqueous particulate suspension comprising:

providing:

supercritical carbon dioxide;

an organic solvent that is substantially soluble in supercritical carbon dioxide;

water; and

a biologically active substance that is soluble in the organic solvent and is substantially insoluble in water and supercritical carbon dioxide;

contacting the organic solvent, water and biologically active substance together to form a solution;

contacting the solution with the supercritical carbon dioxide in an extraction chamber maintained at a temperature and pressure above the critical point of the supercritical carbon dioxide, the supercritical carbon dioxide extracting the organic solvent from the solution and thereby causing the biologically active substance to precipitate in the form of particles that become suspended in water and thus form the aqueous particulate suspension; and

separating the aqueous particulate suspension from the organic solvent by

flowing the organic solvent out of the extraction chamber with the supercritical carbon dioxide via a backpressure regulator,

separately flowing the aqueous particulate suspension out of the extraction chamber and into a collection vessel,

isolating the collection vessel from the extraction chamber, and

draining the aqueous particulate suspension from the collection vessel.

11. The method according to claim 10 wherein the solution further comprises a second solute comprising an excipient selected from the group consisting of polymers, waxes, lipids and combinations thereof, and the particles suspended in water comprise the biologically active substance and the excipient.

12. The method according to claim 10 wherein the organic solvent is selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, alcohols, acetone, ethyl acetate and chloroform.

13. The method according to claim 10 wherein the average particle size of the particles suspended in water is from about 10 nm to about 10 μm.

14. A method of producing a particulate suspension comprising:

providing:

a supercritical fluid;

a first solvent that is soluble in the supercritical fluid;

a second solvent that is substantially insoluble in the supercritical fluid and is at least partially soluble in or miscible with the first solvent; and

a solute that is soluble in the first solvent and is substantially insoluble in the second solvent and the supercritical fluid;

contacting the first solvent, the second solvent and the solute together to form a solution;

contacting the solution with the supercritical fluid in an extraction chamber maintained at a temperature and pressure above the critical point of the supercritical fluid, the supercritical fluid extracting the first solvent from the solution and thereby causing the solute to precipitate in the form of particles that become suspended in the second solvent and thus form the particulate suspension; and

separating the particulate suspension from the first solvent by

flowing the first solvent out of the extraction chamber with the supercritical fluid via a backpressure regulator, and

depressurizing the extraction chamber and collecting the particulate suspension therein.

15. The method according to claim 14 wherein the solute comprises a biologically active substance.

16. The method according to claim 14 wherein the supercritical fluid is selected from the group consisting of supercritical carbon dioxide, dimethylether, straight chain or branched chain C1-C6 alkanes and combinations thereof.

17. The method according to claim 14 wherein the solution further comprises a plurality of solutes and wherein the particles suspended in the second solvent comprise the plurality of solutes.

18. The method according to claim 17 wherein the plurality of solutes comprises a first solute comprising a biologically active substance and a second solute comprising an excipient selected from the group consisting of a polymer, a wax, a lipid and combinations thereof.

19. The method according to claim 14 wherein the first solvent comprises an organic solvent.

20. The method according to claim 19 wherein the first solvent is selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, alcohols, acetone, ethyl acetate and chloroform.

21. The method according to claim 14 wherein the second solvent is water.

22. The method according to claim 14 wherein the average particle size of the particles suspended in the second solvent is from about 10 nm to about 10 μm.

23. A method of producing an aqueous particulate suspension comprising:

providing:

supercritical carbon dioxide;

an organic solvent that is substantially soluble in supercritical carbon dioxide;

water; and

a biologically active substance that is soluble in the organic solvent and is substantially insoluble in water and supercritical carbon dioxide;

contacting the organic solvent, water and biologically active substance together to form a solution;

contacting the solution with the supercritical carbon dioxide in an extraction chamber maintained at a temperature and pressure above the critical point of the supercritical carbon dioxide, the supercritical carbon dioxide extracting the organic solvent from the solution and thereby causing the biologically active substance to precipitate in the form of particles that become suspended in water and thus form the aqueous particulate suspension; and

separating the aqueous particulate suspension from the organic solvent by

flowing the organic solvent out of the extraction chamber with the supercritical carbon dioxide via a backpressure regulator, and

depressurizing the extraction chamber and collecting the aqueous particulate suspension therein.

24. The method according to claim 23 wherein the solution further comprises a second solute comprising an excipient selected from the group consisting of polymers, waxes, lipids and combinations thereof, and the particles suspended in water comprise the biologically active substance and the excipient.

25. The method according to claim 23 wherein the organic solvent is selected from the group consisting of dimethyl formamide, dimethyl sulfoxide, alcohols, acetone, ethyl acetate and chloroform.

26. The method according to claim 23 wherein the average particle size of the particles suspended in water is from about 10 nm to about 10 μm.

Assignments (17)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT R/F 041736/0178 Recorded Apr 21, 2022
From: PNC BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: FERRO CORPORATION
Reel/Frame 059747/0129 →
SECURITY INTEREST Recorded Feb 16, 2017
From: FERRO CORPORATION
To: PNC BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 041736/0178 →
RELEASE OF SECURITY INTEREST Recorded Feb 15, 2017
From: PNC BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: FERRO CORPORATION
Reel/Frame 041718/0307 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (RELEASES RF 024804/0139) Recorded Aug 12, 2014
From: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK)
To: FERRO CORPORATION
Reel/Frame 033522/0755 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (RELEASES RF 024804/0117) Recorded Aug 12, 2014
From: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK)
To: FERRO CORPORATION
Reel/Frame 033522/0839 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (RELEASES RF 024906/0728) Recorded Aug 12, 2014
From: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK)
To: FERRO CORPORATION
Reel/Frame 033522/0875 →
PATENT SECURITY AGREEMENT Recorded Aug 12, 2014
From: FERRO CORPORATION
To: PNC BANK, NATIONAL ASSOCIATION
Reel/Frame 033522/0966 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (RELEASES RF 017527/0047) Recorded Aug 12, 2014
From: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK)
To: FERRO PFANSTIEHL LABORATORIES, INC.
Reel/Frame 033522/0253 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (RELEASES RF 017746/0052) Recorded Aug 12, 2014
From: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK)
To: FERRO PFANSTIEHL LABORATORIES, INC.
Reel/Frame 033522/0284 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Aug 30, 2010
From: FERRO CORPORATION
To: PNC BANK NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK)
Reel/Frame 024906/0728 →
AFTER-ACQUIRED INTELLECTUAL PROPERTY SECURITY AGREEMENT (SECOND SUPPLEMENTAL FILING) Recorded Aug 6, 2010
From: FERRO CORPORATION
To: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK), AS COLLATERAL AGENT
Reel/Frame 024804/0139 →
ATTESTATION & CONFIRMATION OF SECURITY INTEREST Recorded Aug 6, 2010
From: FERRO CORPORATION
To: PNC BANK, NATIONAL ASSOCIATION (AS SUCCESSOR-BY-MERGER TO NATIONAL CITY BANK), AS COLLATERAL AGENT
Reel/Frame 024804/0117 →
RELEASE OF SECURITY INTEREST Recorded Sep 29, 2008
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. (AS SUCCESSOR-IN-INTEREST TO J.P. MORGAN TRUST COMPANY)
To: FERRO CORPORATION
Reel/Frame 021590/0591 →
SECURITY AGREEMENT Recorded Jun 15, 2006
From: FERRO PFANSTIEHL LABORATORIES, INC.
To: J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, AS TRUSTEE
Reel/Frame 017794/0402 →
SECURITY AGREEMENT Recorded Jun 8, 2006
From: FERRO PFANSTIEHL LABORATORIES, INC.
To: NATIONAL CITY BANK, AS COLLATERAL AGENT
Reel/Frame 017746/0052 →
SECURITY AGREEMENT Recorded Apr 26, 2006
From: FERRO PFANSTIEHL LABORATORIES, INC.
To: NATIONAL CITY BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 017527/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2004
From: SHEKUNOV, BORIS Y.; CHATTOPADHYAY, PRATIBHASH; SEITZINGER, JEFFREY S.; HUFF, ROBERT W.
To: FERRO CORPORATION
Reel/Frame 015486/0452 →